GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (STU:HQE1) » Definitions » Research & Development

CytoSorbents (STU:HQE1) Research & Development : €12.72 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is CytoSorbents Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. CytoSorbents's Research & Development for the three months ended in Mar. 2024 was €2.07 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €12.72 Mil.

CytoSorbents Research & Development Historical Data

The historical data trend for CytoSorbents's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Research & Development Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.88 7.24 14.50 14.27 14.42

CytoSorbents Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.94 3.39 3.51 3.76 2.07

CytoSorbents Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoSorbents  (STU:HQE1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CytoSorbents Research & Development Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (STU:HQE1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (STU:HQE1) » Definitions » Research & Development
Comparable Companies
AXDX LUCD NSPR RTGN EAR XAIR RBOT ELUT ICCM NVNO ABT SYK MDT BSX SZSE:300760 DXCM EW ZBH STE XAMS:PHIA
Traded in Other Exchanges
CTSO:USA
Address
305 College Road East, Princeton, NJ, USA, 08540
Website
https://www.cytosorbents.com
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

CytoSorbents (STU:HQE1) Headlines

No Headlines